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Summary. Pgp is expressed on normal haemopoietic 
progenitor cells. The significance of the efflux pump in 
protecting normal progenitors for anthracycline toxicity is 
not defined and is the subject of this study. Pgp was measured 
in CD34+ progenitors with a rhodamine efflux assay. A high 
efflux, modulated by verapamil, was only found in a distinct 
subpopulation (20-30%). Pgp measured by the monoclonal 
antibody antibody (MoAb) MRK-16 was low in the rhod- 
amine dull, but significantly (P<0-04) higher than in the 
rhodamine bright cells. Reverse transcriptase polymerase 
chain reaction (RT-PCR) of MDR1 mRNA showed a very 
weak signal in both populations. In a single-cell clonogenic 
assay, rhodamine dull cells appeared less sensitive to anthra- 
cyclines (IC5() daunorubicin 0-005 jug/ml; adriamycin
0-03 /xg/ml) compared to rhodamine bright cells (IC50 
daunorubicin 0-0025 ¿¿g/ml; adriamycin 0 - 0 1  /¿g/ml). 
Furthermore, verapamil significantly (P<0-05) potentiated 
anthracycline toxicity only in the rhodamine dull cells, 
proving its Pgp-specific modulating effect. Rhodamine dull 
cells gave larger and more mixed colonies compatible with a 
more primitive origin. Although detection with MoAbs and 
RT-PCR revealed a low Pgp level, functionally this Pgp 
appeared to be very important in protecting primitive 
progenitors against anthracycline toxicity. This protection 
can be jeopardized by administration of Pgp modulators.
Keywords: anthracyclines, haemopoietic progenitors, 
MDR1, P-glycoprotein, rhodamine.
Treatment of cancer with chemotherapy may fail due to 
selection for or induction of resistance mechanisms. 
Haematological and non-haematological toxicity limits 
further dose intensification. In the last decade, much 
research focused on a common form of multidrug resistance, 
P-glycoprotein-170 (Pgp) expression. Pgp is a transmem- 
brane-located glycoprotein, encoded by the Multi Drug 
Resistance 1 (MDR1) gene (Ueda et al, 1986). Pgp functions 
as an energy-dependent efflux pump which transports many 
structurally unrelated compounds such as vinca alkaloids, 
taxols, actinomycin D, epipodophyllotoxins, mitoxantrone 
and anthracyclines (Ling, 1992). Several agents, e.g. 
verapamil, are effective modulators of this efflux pump 
(Slater et al, 1986; Hofmann et al, 1992; Weaver et al, 1993; 
Boesch & Loor, 1994).
In vitro experiments with cell lines showed a strong
Correspondence: Dr M. E. P. Smeets, Division of Haematology, 
University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, 
The Netherlands.
correlation between Pgp expression and rhodamine reten­
tion. The efflux assay with the fluorescent dye rhodamine is a 
sensitive method to assess functional MDR1 expression 
(Neyfakh, 1988; Efferth et al, 1989; Ludescher et al, 1992). 
Other methods like PCR of the MDR1 messenger RNA or 
immunostaining with MoAbs for different epitopes (4E3, 
C219, JSB1, MRK16) have also been applied in order to 
determine Pgp expression (Murphy et al, 1990; Noonan et al,
19 90 ; Schinkel et al, 19 91 ; Krishan et al, 19 91 ; Van Acker et 
al, 1993). Conflicting results have been reported using 
different methods (Zhou et al, 1992; Brophy et al, 1994; 
Nussler et al, 1994; Bailly et al, 1995).
Pgp is not only present on malignant cells but also in 
various normal tissues such as blood-brain barrier, jeju­
num, colon, kidney, adrenal gland, biliary and pancreatic 
ductules (Sugawara et al, 1988; Cordon Cardo et al, 1989; 
van der Valk et al, 1990), peripheral blood cells (fractions of 
T and B cells) (Neyfakh et al, 1989; Chaudhary et al, 1992; 
Gupta et al, 1992; Klimecki et al, 1994) and on haemopoietic 
progenitor cells (Drach et al 1992; Marie et al, 1992;
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Hegewisch & Becker, 1993; Licht et al 1994). Chaudhary & 
Roninson (1991) showed, by double staining with rhoda­
mine and MRK16, an inverse correlation between rhoda­
mine retention and Pgp expression on normal human bone 
marrow cells. A low rhodamine retention also corresponded 
with a high CD 3 4 expression and high clonogenic capacity of 
these cells.
Little is known about the physiological function of Pgp on 
haemopoietic progenitors and its significance in protecting 
haemopoietic cells during therapy with cytotoxic drugs. The 
application of Pgp modulators in an attempt to overcome 
drug resistance of malignant cells may be nullified by 
increased toxicity to normal haemopoietic progenitors.
In this study, Pgp expression and function were studied in 
normal CD34+ cells. A high functional Pgp was measured in 
20-30% of the CD34+ cells as indicated by a low retention of 
rhodamine (dull). In a single-cell clonogenic assay these 
rhodamine dull cells proved to be protected against in vivo 
attainable anthracycline concentrations and more primitive 
progenitors in contrast to rhodamine bright cells. Moreover, 
only in the rhodamine dull cells was retention and toxicity 
significantly increased by the modulator verapamil.
were incubated (2 x 105 cells/ml) in Iscove's medium with a 
final rhodamine concentration of 0*1 jug/ml (60 min, 37°C). 
After centrifugation, cells were resuspended in dye-free 
Iscove’s medium with or without 10 ¡xm verapamil (Knoll 
AG, Ludwigshaven, Germany) and incubated at 37°C to 
allow the efflux of the fluorochrome by Pgp. To study time 
dependency of rhodamine uptake and efflux, samples were 
evaluated at various intervals. A time course of 2 h efflux 
was standardized to study maximal differences in functional 
Pgp expression on haemopoietic progenitors.
As anthracyclines are actively pumped out of the cell by 
Pgp, the
MATERIALS AND METHODS
Isolation of CD34+ cells. After obtaining informed consent, 
bone marrow was collected from healthy donors undergoing 
bone marrow harvest for allogeneic bone marrow trans­
plantation. Mononuclear cells were isolated by Ficoll-Paque 
1-077 g/ml (Pharmacia Biotech, Uppsala, Sweden) density 
centrifugation. The interphase cells were collected and 
washed twice with glucose-phosphate buffered saline 
supplemented with 0-5% w/v bovine serum albumin (BSA, 
Fraction V, A-9418, Sigma Chemical Co., St Louis, Mo., 
U.S.A.) (G-PBS-BSA). CD34+ cells were isolated with directly 
conjugated CD34 antibody-coupled immunomagnetic beads 
(M-450, coated with ‘561’ a class III epitope anti-CD34, 
Dynal, Oslo, Norway) using the Dynal protocol. Purity of the 
cells was controlled by labelling with the MoAb HPCA2 
(Becton Dickinson (BD) BV, Etten-Leur, The Netherlands). 
Cells incubated with IgG l-FITC (Dako, Glostrup, Denmark) 
served as control. After washing with G-PBS-BSA, cells were 
resuspended in Iscove's Medium (Life Technologies, Paisley, 
Scotland), supplemented with 5% v/v heat-inactivated fetal 
calf serum (PCS, Hyclone, Logan, Utah, U.S.A.) and 10% v/v
dimethylsulphoxide Merck-Schuchardt,
Germany) at a concentration of O ^-tM x 106 cells/ml and 
cryopreserved in 1 ml vials in liquid nitrogen with a tem­
perature controlled (Kryo 10, Products,
Sunbury-on-Thames, U.K.). Prior to the experiments, cells 
were thawed rapidly in a 3 7°C water bath and diluted in PCS, 
containing 0-02 mg/ml deoxyribonuclease I (DNAse from 
bovine pancreas, Boehringer-Mannheim, Germany), 4 m 
MgS0 4  and 15 U/ml preserved free heparin. After washing 
with G-PBS-BSA the cells were resuspended in Iscove’s 
medium with 10% v/v FCS.
Efflux assay. Rhodamine (Rhl23, Sigma Chemical Co., 
St Louis, Mo„ U.S.A.) was dissolved in distilled water (dll20 ) 
and stored as a sterile stock solution (10 /ug/ml). The cells
assay with
anthracyclines should yield comparable results. Daunorubi­
cin (Rhone-Poulenc Rorer BV, Amstelveen, The Netherlands) 
was dissolved in phosphate buffered saline (PBS) (NPBI BV, 
Emmer-Compascuum, The and at
—20°C as a sterile stock (50 jig/ml). After loading the cells 
with 2/ig/ml daunorubicin (60 min, 37°C), the same efflux 
procedure was applied. Cellular rhodamine and daunorubi­
cin content were measured by flow cytometry.
Flow cytometric measurement of dye content and single-cell 
sorting. For the measurement of cellular dye content as well 
as single-cell sorting, a Coulter Epics Elite Flow cytometer, 
equipped with an autoclone device (Coulter, Miami, Florida) 
was used. Cells were excited with a single Argon ion laser 
emitting at 488 nm, running at 15mW (standard setting). 
Gating on forward and right angle scatter was used to 
exclude dead cells and debris. Fluorescence intensity of 
cellular rhodamine and daunorubicin were measured using 
respectively a 515 nm and a 550 nm long pass filter. After 
2  h efflux, 25% of the cells with the highest (bright) or lowest 
(dull) rhodamine content were sorted to elucidate differences 
between cells with respectively a relatively low or high 
functional Pgp expression.
Rhodamine uptake assay. After sorting rhodamine dull and
+ cells, a second incubation (without efflux) with
(> 1 jug/ml rhodamine (60 min, 37°C) (2 x 1 0 4 cells/0 -5 ml 
Iscove's medium) in the presence or absence of 10 jam 
verapamil was performed. After 60 min incubation, rhoda­
mine retention was at a steady state, as a result of an 
equilibrium between uptake and efflux. As verapamil blocks 
the Pgp dependent efflux, differences in rhodamine content
Immunostalning for Pgp, For immunostaining of Pgp, two
s were applied: C219 (Centocor Corporation, 
Malver, Pa., U.S.A.) recognizes an internal, and MRK16
Biomedical Company, Thousand 
U.S.A.) an external Pgp epitope. Before staining with C219, 
rhodamine dull and bright CD34+ cells were sorted, pelleted 
and fixed in I ml Permeafix (Ortho Diagnostic Systems Inc., 
Raritan, N.J., U.S.A.) (room temperature, 40 min) followed by 
10 min incubation in G-PBS-BSA. After incubation (4°C, 
IO min) in 20% v/v pooled human serum/PBS to block non­
specific binding, cells were incubated with 2  peg mouse anti- 
human C219 (4°C, 30 min), washed with G-PBS-BSA (4°C) 
and then stained with goat anti-mouse IgG-FITC
(4 C, 301 
After the rhod efflux assay, viable cells were
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for non-specific binding cells. Thereafter, 5 pg mouse anti­
human MRK16 was added to the pellet (4°C, 30 min). Next, 
cells were washed with G-PBS-BSA (4°C) and incubated with 
goat anti-mouse IgG-PE (DAKO) (4°C, 30 min). After a final 
wash step with G-PBS-BSA, analysis was performed flow 
cytometrically (standard setting) using a 550 dichroic 
mirror with a 525 band pass filter or a 575 band pass 
filter to measure respectively the FITC and PE signal. The 
MRK16 signal was measured in subpopulations by gating 
25% of the most rhodamine dull and rhodamine bright cells. 
Appropriate isotype controls (mouse anti-human IgG/IgG2 a) 
were used in the control tubes. The staining procedure was 
validated on the cell line A2780/dox5.
RNA isolation and RT-PCR of the MDR1 expression. RNA was 
extracted using the guanidium thiocyanate acid phenol 
chloroform procedure (Puissant & Houdebine, 1990). The 
samples were stored at — 80°C. The cDNA synthesis reaction 
was performed in a total volume of 20 pi, containing 50 nw 
Tris-HCl (pH 8-3), 75 nM KC1, 1-5 mM MgCl2, lOmM DTT, 
625[M dNTPs, SpA random hexamers (Pharmacia, 
Uppsala, Sweden), 20 U RNAsin (Promega, Madison, Wis., 
U.S.A.) and 200 U Mo-MLV reverse transcriptase (Life 
Technologies). To this suspension 5 /u.1 of RNA or dH20 was 
added, and the mixture was overlaid with 70 pi mineral oil. 
The RT reaction was performed for 10 min at 20°C, 45 min 
at 42°C, 10min at 95°C, and subsequent cooling to 4°C. 
After cDNA synthesis the total volume was increased up to 
100Atl containing 50mM KC1, 20mM Tris pH 8-4, 1-5 mM 
MgCl2, 0 001% gelatin, 0-251 mM dNTPs, 30pmol of each 
primer and 2-5 U Taq polymerase (Gibco BRL, Gaithersburg, 
Md., U.S.A.). PCR amplification was performed in a thermo­
cycler; 94°C for 5 min, followed by 35 cycles of 94°C for 
1*5 min (rhodamine dull), 55°C for 2 min, 72°C for 2 min. 
After the last cycle the extension phase was prolonged up to 
10 min and the samples were cooled at 4°C. MDR1 and B2M 
primers are presented in Table I. A sample of 15 pi of the PCR 
product was loaded onto 2 % agarose gel and analysed by 
electrophoresis and Southern blotting using standard 
procedures. Procedures were validated by analysis of the 
cell line A2 780/dox 5.
Single-cell clonogenic assay. As retention and toxicity of 
anthracyclines is influenced by Pgp expression, haemo­
poietic progenitors with a relatively high functional Pgp 
(rhodamine dull) are expected to be protected for these 
drugs. Single rhodamine dull or rhodamine bright cells were 
sorted in round-bottom 96-well plates (Costar no. 3799, 
Cambridge, Mass., U.S.A.), prefilled with 75 p i liquid medium 
A. Medium A consisted Iscoves, 2mM glutamine (Flow 
Laboraties, Irvine, Scotland), streptomycin 50 jug/ml, peni­
cillin 50IU/ml (Flow Laboraties) supplemented with 20% 
v/v FCS, 5% w/v BSA, 0-3 mg/ml human transferrin, 50 pM 
2-jS-mercaptoethanol (both from Sigma, St Louis, Mo., 
U.S.A.) and recombinant growth factors, G-CSF (20ng/ml), 
SCF (25ng/ml) (both from Amgen, Thousand Oaks, Calif., 
U.S.A.), IL-3 (50ng/ml) (Sandoz, Basel, Switserland), GM- 
CSF (2 0 ng/ml) (Sandoz) and Erythropoietin (l-5U/ml) 
(Cilag, Herentals, Belgium). Adriamycin (Farmitalia Carlo 
Erba, Belgium) or daunorubicin was added to medium A at 
increasing concentrations (range 0 -0 0 0 1 -0 - 1  ug/ml) with
Table I. Primer sequences.
MDlll primers are derived from EMBL/GenBank sequence 
accession number M14 7 58 :
MDR1-5: TGC TGG TTG CTG CTT ACA TTC 
MDR.1-3: GCC AAA ATC ACA AGG GTT AGC 
MDR 1-int: ACA TCA TCT GTA AGT CG G GTG TT
B2M primers are derived from the EMBL/GenBank sequence 
accession number M l 7986 and M l 798 7:
B2M-5 CTC GCG CTA CTC TCT CTT TCT
B2M-3 : TGT CGG ATT GAT GAA ACC CAG
B2M-int: CAG GTT TAC TCA CGT CAT CCA GCA GAG AAT
or without 10 pM verapamil. The 9 6 -well plates were placed 
in an incubator at 37°C, 5% C02, in a fully humidified 
atmosphere. One day after sorting, single cells were found in 
>90% of the wells. In each individual well the total cell 
number was counted under an inverted microscope on days 
4,11 and 18 to evaluate the clonogenic capacity, duration of 
proliferation, and growth inhibition. All experiments were 
performed at least in triplicate. After plotting of the dose- 
response curves, the 50% inhibitory concentration (IC50) of 
the anthracyclines for the rhodamine dull and bright cells 
was calculated. Colonies (>50 cells/well) were morphologi­
cally identified as a colony of granulocytes/monocytes, a 
colony of erythrocytes, or a mixed colony defined as a 
mixture of granulocytes/monocytes and erythrocytes. Mor­
phological analysis of large colonies (>5000 cells/well) was 
controlled by immunostaining with the MoAbs glycoferrine- 
PE (Coulter) to identify erythrocytes, CD14-PE (BD) to iden­
tify monocytes and CD15-FITC (BD) to identify granulocytes.
Cell line. The adherent Multidrug Resistant ovarian 
carcinoma cell line A2780/dox5 (Alaoui Jamali et al, 
1989) and the parent cell line A2780/WT were routinely 
cultured in Iscove’s medium (Gibco) supplemented with 10% 
v/v FCS, 2 m M  glutamin, 100IU/ml penicillin at 37°C in a 
humidified atmosphere with 5% C02. Exponentially growing 
cells were used for the experiments.
Statistical analysis, The Wilcoxon Mann-Whitney U or 
Student’s i-test was applied for statistical analysis of the 
results.
RESULTS
Dye retention and modulation by verapamil 
After 1 h of incubation with rhodamine, all CD34+ cells 
contained rhodamine (Fig 1). No distinct subpopulation with 
a different rhodamine content was observed. However, after 
resuspension in dye-free medium the efflux was hetero­
genous. A relatively fast efflux was observed only in a 
subpopulation of the CD34+ cells. Within 2h efflux, a 
distinct rhodamine dull subpopulation of 20-30% of the 
cells with a rhodamine content below the initial uptake 
could be distinguished. During prolonged exposure the efflux 
slowed down, but no plateau was observed. After 2 h 
incubation of rhodamine loaded cells in rhodamine free 
medium containing verapamil, almost no decrease of 
rhodamine content was measured (Fig 2).
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Fig 1. Representative example of rhodamine efflux in normal CD34+ cells. After 1 h incubation all cells showed a high rhodamine uptake 
(rhodamine bright). Rhodamine efflux was observed in all cells. However, a subpopulation of the cells initially showed a relatively fast rhodamine 
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Fig 2. Rhodamine content of normal CD3-4* 
cells after 2 h efflux in dye free medium 
without (1) and with (2) verapamil. Sorting 
experiments were performed according to the 
gate setting Ai (25% of the most rhodamine 
dull cells) and Bi (25% of the most rhodamine
bright cells).
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Fig 3. Representative sample of rhodamine (A) 
and daunorubicin (B) content in CD34+ cells 
after 2 h of efflux without (1) or with 10 /xm 
verapamil (2).
The daunorubicin efflux assay yielded similar results. A 
comparable fraction (20-30%) of the CD34+ cells showed a 
strong daunorubicin efflux resulting in a low content of 
daunorubicin (daunorubicin dull). In the presence of 
verapamil the efflux of daunorubicin was blocked and an 
increased retention of daunorubicin was observed (Fig 3).
Modulation of rhodamine or daunorubicin efflux in the 
presence of verapamil strongly suggests the expression of 
functional Pgp. To affirm the differences in functional Pgp 
expression between rhodamine dull and bright cells, 25% of 
the most rhodamine dull and 25% of the most rhodamine 
bright cells, were sorted. In the presence of verapamil a 2-7- 
fold higher increase of rhodamine retention was measured in 
the rhodamine dull cells compared to a I-1 -fold increase in 
the rhodamine bright cells as shown in Fig 4.
Immunostaining for Pgp expression
Staining with the MoAbs C219 against an internal and 
MRK16 against an external epitope was weak in both the 
rhodamine dull and bright cells. No significant quantitative 
differences in Pgp were measured with C219. Staining with 
MRK16 yielded a significantly (P<0-04) stronger signal in 
the rhodamine dull cells compared to the rhodamine bright 
cells (Table II). Measurement of Pgp with MRK16 on the cell 
line A2780/dox5 versus A2780/WT showed a much 
stronger signal (mean fluorescence A2780/dox5/A2780/ 
WT: 8-3).
RT-PCR o/MDRl mRNA
The results of southern blotting of the RT-PCR and screening 
with the MDR-int of rhodamine dull and bright CD34+
cells are shown in Fig 5. A weak positive signal for the 
MDRl-mRNA was visible in both rhodamine dull and 
rhodamine bright cells, compared to the cell line A2780/ 
dox5. No significant quantitative differences in MDR1 mRNA 
could be detected between the rhodamine dull and bright 
cells after correction for the /32M signal. Semi-quantative 
analysis was not feasible, as the RT-PCR analysis of CD34+ 
cells was only positive after 35 cycles.
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Fig 7. Dose-response curve of daunorubicin for rhodamine dull (A) 
and bright (B) CD34+ cells without and with 10 ¡jlm verapamil 
(corrected for the mean intrinsic toxicity of verapamil <10%). A 
significant (P<0-04) modulation of toxicity was measured in the 
rhodamine dull, not in the rhodamine bright cells.
Table III. Proliferative capacity of CD34+ cells.
Proliferative capacity of rhodamine dull and 
rhodamine bright cells (% of wells in 96-well plate)1
>50 cells 
dull/bright
>500 cells 
dull/bright
> 5000 cells 
dull/bright
Mean (%) 
P value
32/25
0-003
24/13
0-0002
15/3
0-0002
Morphology of colonies >50 cells2
Granulocytes 
or monocytes 
dull/bright
Erythrocytes
dull/bright
Mixed3
dull/bright
Mean (%) 
P value
63/75
n.s.4
25/21
n.s.
13/0
0-05
rhodamine bright cells revealed no differences in percentage 
of colonies of erythrocytes colonies (25% and 21%) or 
granulocytes/monocytes colonies (63% and 75%). The 
percentage of mixed colonies grown from rhodamine dull 
cells (13%) was significantly (P<(>05) higher compared to 
rhodamine bright cells (<1%) (Table III). Immunostaining 
with MoAbs of large colonies confirmed the morphological 
analysis (data not shown).
1 Mean of 14 experiments. * Mean of 10 experiments. 3 Granulo­
cytes or monocytes and erythrocytes. 4 n.s. = not significant.
DISCUSSION
To study the functional relevance of Pgp on normal 
haemopoietic progenitors we used purified CD34+ haemo­
poietic cells from healthy bone marrow donors. During 
rhodamine exposure the rhodamine fluorescence was rather 
homogenous. Only after 2h of efflux could a distinct 
subpopulation of 20-30% of the CD34+ cells be character­
ized as rhodamine dull, suggesting a relatively high Pgp 
expression. Anthracyclines, also actively effluxed by Pgp, 
showed comparable results. 20-30% of the cells became 
daunorubicin dull after 2h efflux. Both rhodamine and 
daunorubicin efflux could be completely inhibited by 
verapamil, which is strongly suggestive for active Pgp 
function. By forward scatter, the size of rhodamine or 
daunorubicin bright cells was 2 -fold larger compared to the 
size of rhodamine dull cells. However, differences in 
rhodamine retention were 4-6-fold. Moreover, differences 
in efflux and efflux inhibition by verapamil is independent of 
the cell size. As rhodamine also stains mitochondria, the 
number and activity of mitochondria may influence 
rhodamine retention. Darzynkiewicz et al (1981) showed 
an increase in rhodamine retention was most probably due 
to increased mitochondrial binding. We studied the rhoda­
mine dull and bright cells by electron microscopy. No 
differences in morphology of the cells or number of 
mitochondria could be detected (data not shown). In 
addition, staining and efflux studies with daunorubicin not 
preferentially bound to mitochondria, revealed similar 
results to rhodamine.
MDR1 expression measured by RT-PCR of the mRNA or 
staining with the MoAb C219 showed no significant 
quantitative differences between rhodamine dull and bright 
cells, Pgp detected by MRK16 was also very weak compared 
to the MDRl-positive cell line. However, the MRK16 signal 
was significantly stronger on the rhodamine dull cells versus 
the rhodamine bright cells in accordance with the observed 
differences in functional Pgp. Therefore the efflux assay is the 
most sensitive method to detect small subsets of cells with a 
high Pgp, remaining obscure by other methods.
The presence of Pgp on haemopoietic progenitors has 
already been observed by others; however, its functional 
relevance in protecting haemopoietic cells has not yet been 
proved. By studying anthracycline toxicity to progenitors 
with a high and low or negligible Pgp we proved the 
importance of Pgp on the most primitive progenitors. In a 
single cell clonogenic assay we showed that the rhodamine 
dull cells are indeed protected against anthracycline toxicity 
by its Pgp, The IC50 values of anthracyclines were 2-3-fold 
higher for the rhodamine dull cells compared to the bright
© 1997 Blackwell Science Ltd, British Journal of Haematology 96: 346-355
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cells. These results are even more relevant since 
concentrations of anthracyclines used in our assay were in 
the same range of in vivo achievable concentrations (Speth et 
al 1988).
Using optimal concentrations, Pgp modulators enhanced 
the toxic effects of anthracyclines on the rhodamine dull 
progenitors. Haematological toxicity of modulators has been 
reported in clinical trials (Figueredo et al, 1990; Scheithauer 
et al, 1993; Bartlett et al, 1994). Pgp modulation on 
haemopoietic progenitors and also pharmacokinetic changes 
of the cytotoxic drug due to Pgp modulation on liver or 
kidney have been suggested. Nakarai & Koizumi (1990) and 
Visani et al (1993) showed that calcium antagonists 
increased toxicity to haemopoietic progenitors in vitro. 
Whether these observations were due to specific Pgp modu­
lation was not proved. Aspecific intrinsic or intracellular 
effects such as redistribution of the cytostatic drug were not 
excluded. Therefore we studied the effects of verapamil on 
progenitors with a functional high and low or negligible Pgp. 
In accordance with the high Pgp expression, increased 
toxicity of anthracyclines in the presence of verapamil was 
significant only for the rhodamine dull cells. Thus the 
increased toxicity was the result of specific Pgp modulation of 
the haemopoietic progenitors. This clonogenic assay is an 
appropriate tool to test efficacy, aspecific (intrinsic) haema­
tological toxicity and specific Pgp mediated toxicity of 
potential Pgp modulators in combination with anticancer 
drugs.
Chaudhary & Roninson (1991) showed an inverse 
correlation between rhodamine retention and clonogenic 
capacity in normal bone marrow cells. Other investigators 
confirmed the correlation between rhodamine retention and 
clonogenic capacity (Bertoncello et al, 1985; Mulder et al, 
1987; ITdomsaki et al, 1991). By means of a mouse trans­
plant model it has been proved that the bone marrow 
repopulating capacity of cells can be predicted on the basis of 
rhodamine retention (Ploemacher et al, 1988). Within the 
CD34+ population, rhodamine retention was also inversely 
correlated with clonogenic capacity. The rhodamine dull 
cells showed a higher clonogenic and proliferative capacity 
expressed as a higher number, with larger and more mixed 
colonies. We confirmed the more primitive origin of pro­
genitors with a high Pgp expression, the CD34+ rhodamine 
dull cells. The more primitive progenitors are protected 
against various toxic agents by this physiological defensive
nism. We showed that this can bt 
by verapamil in this fraction, is held
responsible for haemopoietic recovery. After cytoreductive 
therapy in the presence of a Pgp modulator, the toxicity will 
increase most abundantly in the more primitive rhodamine 
dull progenitors. Morbidity and mortality due to this toxicity 
might counterbalance the improved anticancer efficacy, An 
approach for circumventing unacceptable haematological 
toxicity is reinfusion of bone marrow or peripheral stem 
cells. To make dose intensification feasible, up-regulation of 
MDR1 expression in haemopoietic stem cells by means of 
transvection of MDRl-cDNA with the use of retroviruses has 
also been suggested (Bertolini et al, 1994; Ward et al, 1994; 
Schwarzenberger et al, 1996). Our results prove the clinical
significance of MDR1 function at least in the more primitive
+ rhodamine dull cells. Although by means of PCR or 
MoAbs MDR1 expression seems to be low, functionally it 
appeared important in protecting and reducing sensitivity to 
anticancer drugs such as anthracyclines. MDR-1 transvec­
tion is not likely to improve the resistance of primitive 
progenitor cells to Pgp-dependent drugs.
In this study we showed that the more primitive progenitor 
cells within the CD34+ bone marrow fraction have a func-
that this pump plays an 
cells against pharmaco-
tionally important Pgp. We s 
important role in protecting
attainable 1« n  t
will increase toxicity within
fraction, held
recovery. We have proved that the potentiation of anthra­
cycline toxicity in these cells is the result of specific Pgp 
modulation on these cells.
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